Al-Ola Abdallah, Associate Professor at the University of Kansas Medical Center, shared a post on LinkedIn:
“The oncology blockbuster race in 2025:
Keytruda leads at $31.6B, followed by Darzalex at an impressive $14.35B and Opdivo at $10B—remarkably, a Multiple Myeloma therapy now ranks N2 among the world’s top-selling oncology drugs!”
